Urinary and Serum Biomarkers Help Predict COVID-19 Outcomes, Study Reveals

A recent study has revealed that urinary and serum biomarkers may help the early detection of acute kidney injury or AKI in patients with COVID-19, signaling renal involvement and the potential need for greater medical attention.

Photo: Medical Professionals Attending Patient | InStyleHealth


Experts performed a retrospective observational study on 199 adult patients with COVID-19. Urinalysis had been performed using a biochemical and flow cytometer sediment analyzer, while appropriate assays were performed on serum samples.

Eventually, 12.1% of patients needed intensive care. The levels of urinary biomarkers, such as glucose, protein, and ketones were significantly changed in these patients. The same was true for serum molecules such as sodium and albumin.

There were similar patterns observed for AKI, which developed in 15 patients over COVID-19’s clinical course. Urinary pH as well as the presence of blood, protein, and nitrite were all indicative of the risk of AKI, as were serum levels of urate, chloride, and creatinine.

The receiver operating characteristic or ROC curve analysis uncovered that the combination between blood in the urine and chronic kidney disease had the best predictive capacity for AKI, with an area under the curve or AUC of 0.676.

Remarkably, ROC analysis also revealed that combinations of biomarkers could help predict COVID-19 mortality. Particularly, blood in urine and serum lactate dehydrogenase appeared to be a powerful combination, generating an AUC of 0.923.

 

 

Source: Sci Rep 2021;11:11134

If you have any suggestions, please let us know.

Post a Comment (0)
Previous Post Next Post